| dc.creator | Karampitsakos T., Papaioannou O., Dimeas I., Tsiri P., Sotiropoulou V., Tomos I., Papanikolaou I.C., Katsaras M., Kirgou P., Daniil Z., Gourgoulianis K.I., Sampsonas F., Manali E., Papiris S., Bouros D., Tzouvelekis A. | en |
| dc.date.accessioned | 2023-01-31T08:31:18Z | |
| dc.date.available | 2023-01-31T08:31:18Z | |
| dc.date.issued | 2022 | |
| dc.identifier | 10.1183/23120541.00082-2022 | |
| dc.identifier.issn | 23120541 | |
| dc.identifier.uri | http://hdl.handle.net/11615/74409 | |
| dc.description.abstract | [No abstract available] | en |
| dc.language.iso | en | en |
| dc.source | ERJ Open Research | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130766525&doi=10.1183%2f23120541.00082-2022&partnerID=40&md5=e2fac62cdb324f770a78256d5e6bbdb0 | |
| dc.subject | antifibrotic agent | en |
| dc.subject | B cell activating factor receptor | en |
| dc.subject | carbon monoxide | en |
| dc.subject | messenger RNA | en |
| dc.subject | RNA vaccine | en |
| dc.subject | tozinameran | en |
| dc.subject | bronchiectasis | en |
| dc.subject | coronavirus disease 2019 | en |
| dc.subject | disease activity | en |
| dc.subject | down regulation | en |
| dc.subject | fibrosing alveolitis | en |
| dc.subject | forced expiratory volume | en |
| dc.subject | forced vital capacity | en |
| dc.subject | human | en |
| dc.subject | immune response | en |
| dc.subject | immunocompromised patient | en |
| dc.subject | immunogenicity | en |
| dc.subject | immunosuppressive treatment | en |
| dc.subject | Kolmogorov Smirnov test | en |
| dc.subject | Letter | en |
| dc.subject | lung artery pressure | en |
| dc.subject | mortality | en |
| dc.subject | obesity | en |
| dc.subject | practice guideline | en |
| dc.subject | prevalence | en |
| dc.subject | public health | en |
| dc.subject | risk factor | en |
| dc.subject | Severe acute respiratory syndrome coronavirus 2 | en |
| dc.subject | vaccination | en |
| dc.subject | European Respiratory Society | en |
| dc.title | Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis | en |
| dc.type | other | en |